Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis

Table 1 Demographic and disease-specific baseline characteristics of the 22 included patients

Characteristic	n = 22
Gender, n (m/f)	9/13
Age at admission (yr, mean ± SEM)	33.2 ± 7.1 (range: 18-66)
Age at first diagnosis (yr, mean ± SEM)	25.5 ± 5.6 (n = 21, uk in 1) (range: 14-58)
Disease duration at admission (yr, mean ± SEM )	6.2 ± 1.3 (n = 21, uk in 1) (range: 0-19)
Disease extent according to Montreal classification at admission, n (E2:E3)	4:18
Previous anti-TNFα therapy failure, n (%)	5/22 (22.7)
Previous thiopurine therapy, n (%)	9/22 (40.9)
Systemic steroid therapy at admission, n (%)	15/22 (68.2)
Oral mesalamine at admission, n (%)	15/22 (68.2)
Anti-TNFα therapy at admission, n (%)	1/22 (4.5) (third infliximab infusion had been applied 23 d prior to admission)
Thiopurine therapy at admission, n (%)	1/22 (4.5) (on azathioprine for 32 mo prior to admission)
Body mass index (BMI) at admission (kg/m2, mean ± SEM)	20.3 ± 4.3 (range: 12.1-26.8)
Body temperature at admission (°C, mean ± SEM)	38.0 ± 0.2 (range: 36.6-39.6)
Heart rate at admission (beats per minute, mean ± SEM)	97.2 ± 2.9 (range: 80-135)
Number of bowel movements per 24 h at admission (mean ± SEM)	13.5 ± 1.4 (range: 7-30)
Presence of bloody stools at admission, n (%)	22/22 (100)
Plasma CRP concentration at hospital admission (mg/L, mean ± SEM)	87.5 ± 14.3 (range: 2.0-310.4)
WBC count at admission (/nL, mean ± SEM)	12.6 ± 1.0 (range: 4.4-22.8)
Platelet count at admission (/nL, mean ± SEM)	453 ± 29 (232-724)
Blood hemoglobin concentration at admission (g/dL, mean ± SEM)	10.8 ± 0.3 (7.7-14.5)
Endoscopic Mayo score at admission, n (Mayo 2:Mayo 3) (sigmoidoscopy)	7:15

n: Number; m: Male; f: Female; SEM: Standard error of the mean; TNF: Tumor necrosis factor; CRP: C-reactive protein; uk: Unknown; WBC: White blood cell.